It is currently being tested in a phase 1 clinical trial in patients with intermediate-2 or high-risk MDS (NCT03516591), and the results of this study will provide more information on the efficacy of this agent in depleting the CD33-expressing malignant clone and MDSCs, as well as the clinical benefit from it. Here, CD33 is linked to myelodysplastic syndrome.